DeepAI AI Chat
Log In Sign Up

EXSCALATE: An extreme-scale in-silico virtual screening platform to evaluate 1 trillion compounds in 60 hours on 81 PFLOPS supercomputers

by   Davide Gadioli, et al.

The social and economic impact of the COVID-19 pandemic demands the reduction of the time required to find a therapeutic cure. In the contest of urgent computing, we re-designed the Exscalate molecular docking platform to benefit from heterogeneous computation nodes and to avoid scaling issues. We deployed the Exscalate platform on two top European supercomputers (CINECA-Marconi100 and ENI-HPC5), with a combined computational power of 81 PFLOPS, to evaluate the interaction between 70 billions of small molecules and 15 binding-sites of 12 viral proteins of Sars-Cov2. The experiment lasted 60 hours and overall it performed a trillion of evaluations.


page 3

page 5

page 7


Large-scale ligand-based virtual screening for SARS-CoV-2 inhibitors using deep neural networks

Due to the current severe acute respiratory syndrome coronavirus 2 (SARS...

Distributed Computing in a Pandemic: A Review of Technologies Available for Tackling COVID-19

The current COVID-19 global pandemic caused by the SARS-CoV-2 betacorona...

Tunable and Portable Extreme-Scale Drug Discovery Platform at Exascale: the LIGATE Approach

Today digital revolution is having a dramatic impact on the pharmaceutic...

Cloud-Based Real-Time Molecular Screening Platform with MolFormer

With the prospect of automating a number of chemical tasks with high fid...

Sharing pandemic vaccination certificates through blockchain: Case study and performance evaluation

This work proposes a scalable, blockchain-based platform for the secure ...

Stochastic-based Neural Network hardware acceleration for an efficient ligand-based virtual screening

Artificial Neural Networks (ANN) have been popularized in many science a...